A
AARD
Aardvark Therapeutics
4.300
+0.210+5.13%After Hours: 4.400 +0.100 +2.33%19:45 04/02 EDT
OPEN/PREV CLOSE3.920/4.090
TODAY RANGE3.900-4.300
VOL134.75K
MARKET CAP93.81M
52 WEEK RANGE3.350-17.94
AVG VOL (3M)291.41K
% TURNOVER0.62%
TURNOVER--
P/E (TTM)-1.4653
% RANGE9.78%
EPS(TTM)-2.9346
P/E(FORWARD)-1.2356
P/B0.8797
BVPS4.888
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP78.66M
SHARES OUTSTANDING21.82M
NEXT EARNINGS05/12-05/18
FREE FLOAT18.29M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Reuters·03/25 08:01
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
TipRanks·03/24 12:42
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
TipRanks·03/24 11:36
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
Dow Jones·03/24 11:09
Aardvark Therapeutics Price Target Maintained With a $9.00/Share by BTIG
Benzinga·03/24 10:59
BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $9 Price Target
TipRanks·03/24 10:37
Aardvark Therapeutics Establishes $150 Million Equity Program
Reuters·03/24 07:39
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.